Search Orphan Drug Designations and Approvals
-
| Generic Name: | lisocabtagene maraleucel | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Name: | Breyanzi | ||||||||||||||||
| Date Designated: | 10/04/2016 | ||||||||||||||||
| Orphan Designation: | Treatment of chronic lymphocytic leukemia | ||||||||||||||||
| Orphan Designation Status: | Designated/Approved | ||||||||||||||||
| Sponsor: |
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company 400 Dexter Avenue North Suite 1200 Seattle, Washington 98109 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
||||||||||||||||
Marketing approved: |
|||||||||||||||||
| 1 | Generic Name: | lisocabtagene maraleucel |
|---|---|---|
| Trade Name: | Breyanzi | |
| Marketing Approval Date: | 03/14/2024 | |
| Approved Labeled Indication: | treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least 2 prior lines of therapy including, a Bruton tyrosine kinase (BTK) inhibitor and a B-cell lymphoma 2 (BCL-2) inhibitor | |
| Exclusivity End Date: | 03/14/2031 | |
| Exclusivity Protected Indication* : | treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least 2 prior lines of therapy including, a Bruton tyrosine kinase (BTK) inhibitor and a B-cell lymphoma 2 (BCL-2) inhibitor | |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-







